| Literature DB >> 25429436 |
Jesper Lykkegaard1, Pia V Larsen1, Maja S Paulsen1, Jens Søndergaard1.
Abstract
BACKGROUND: The tendency of general practitioners (GPs) to conduct home visits is considered an important aspect of practices' accessibility and quality of care. AIMS: To investigate whether GPs' tendency to conduct home visits affects 30-day readmission or death after hospitalisation with chronic obstructive pulmonary disease.Entities:
Mesh:
Year: 2014 PMID: 25429436 PMCID: PMC4304430 DOI: 10.1038/npjpcrm.2014.100
Source DB: PubMed Journal: NPJ Prim Care Respir Med ISSN: 2055-1010 Impact factor: 2.871
Figure 1Flowchart.
Baseline characteristics of in-patients and excluded patients first-time hospitalised with COPD and the general practice at which they were listed at the time of admission to hospital
|
|
| P
| |
|---|---|---|---|
| Number of patients | 15,545 | 4,851 | |
| Mortality during hospitalisation | 7.2% (6.8–7.6) | 7.2% (6.5–7.9) | 0.98 |
| Readmitted or dead 30 days after discharged alive | 20.8% (20.1–21.5) | 21.0% (19.8–22.2) | 0.80 |
| GP home visit in the year before hospitalisation | 32.9% (32.1–33.6) | 32.5% (31.2–33.8) | 0.66 |
| [Age] in years | 72.4 (72.2–72.6) | 71.8 (71.5–72.2) | <0.01 |
| Proportion of females | 52.8% (52.0–53.6) | 55.9% (54.6–57.3) | <0.01 |
| [Charlson comorbidity index excluding COPD] | 1.25 (1.22–1.27) | 1.22 (1.18–1.27) | 0.36 |
| [Number of GPs in the practice]* | 2.33 (2.31–2.36) | 1.49 (1.46–1.51) | <0.01 |
| [Age of GPs in the practice] in years* | 54.0 (53.9–54.1) | 53.8 (53.5–54.0) | 0.05 |
| [Proportion of female GPs in the practice]* | 28.5% (28.0–29.0) | 32.7% (31.5–33.9) | <0.01 |
| [Area average annual household income] in 1,000 USD | 82.6 (82.5–82.8) | 82.5 (81.9–83.0) | 0.30 |
| [Travel distance to hospital] in kilometres | 15.7 (15.3–16.0) | 13.9 (13.2–14.5) | <0.01 |
| [Municipality urbanisation percentage] | 87.7% (87.4–87.9) | 90.5% (90.2–90.8) | <0.01 |
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; GP, general practitioner; USD, United States Dollars.
[Squared brackets] indicate the means. In year 2008, 1 USD=5.28 Danish crowns. The *-marked estimates disregarded the 238 patients who were excluded for not being listed with a general practice.
Analysis of the odds of having had a GP home visit and the readmission-free survival for patients first-time hospitalised with COPD
|
|
|
| ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Total | 100 | 31 | 21 | |||
|
| ||||||
| 0 | 7 | 22 | 1 | 23 | 1.20 (1.03–1.40) | 1.18 (1.01–1.37) |
| >0–20 | 18 | 25 | 1.21 (0.87–1.69) | 21 | 1.07 (0.95–1.21) | 1.05 (0.93–1.17) |
| >20–30 | 24 | 27 | 1.32 (0.97–1.80) | 20 | 1 | 1 |
| >30–40 | 20 | 33 | 1.83 (1.32–2.54) | 20 | 1.03 (0.92–1.16) | 1.04 (0.93–1.17) |
| >40–60 | 25 | 38 | 2.32 (1.73–3.10) | 21 | 1.10 (0.98–1.23) | 1.09 (0.98–1.22) |
| >60 | 6 | 40 | 2.47 (1.74–3.54) | 24 | 1.25 (1.06–1.47) | 1.23 (1.04–1.44) |
|
| ||||||
| Female | 53 | 35 | 1 | 19 | 1 | 1 |
| Male | 47 | 27 | 0.63 (0.59–0.68) | 23 | 1.23 (1.14–1.32) | 1.20 (1.11–1.29) |
|
| ||||||
| 45–59 | 13 | 12 | 1 | 16 | 1 | 1 |
| 60–79 | 59 | 26 | 2.33 (2.03–2.68) | 20 | 1.25 (1.11–1.41) | 1.21 (1.07–1.36) |
| >79 | 28 | 51 | 7.07 (6.10–8.20) | 24 | 1.39 (1.22–1.58) | 1.38 (1.22–1.57) |
|
| ||||||
| 0 | 45 | 23 | 1 | 16 | 1 | 1 |
| 1 | 22 | 35 | 1.63 (1.48–1.79) | 21 | 1.35 (1.22–1.49) | 1.33 (1.20–1.46) |
| >1 | 33 | 39 | 2.02 (1.86–2.20) | 27 | 1.76 (1.61–1.91) | 1.73 (1.59–1.89) |
|
| ||||||
| 0–2 | 16 | 35 | 1 | 21 | 1 | 1 |
| >2–5 | 21 | 31 | 0.92 (0.82–1.04) | 21 | 1.01 (0.90–1.14) | 0.98 (0.87–1.10) |
| >5–10 | 14 | 28 | 0.82 (0.71–0.94) | 21 | 1.01 (0.89–1.16) | 1.00 (0.88–1.14) |
| >10–20 | 20 | 30 | 0.79 (0.69–0.91) | 21 | 0.97 (0.86–1.11) | 1.03 (0.89–1.18) |
| >20–30 | 14 | 30 | 0.75 (0.64–0.87) | 20 | 0.93 (0.81–1.08) | 0.95 (0.81–1.11) |
| >30 | 15 | 31 | 0.80 (0.68–0.93) | 20 | 0.97 (0.85–1.11) | 0.97 (0.83–1.13) |
|
| ||||||
| 1 | 38 | 30 | 1 | 21 | 1 | 1 |
| 2 | 24 | 31 | 1.10 (0.98–1.22) | 22 | 1.03 (0.93–1.13) | 1.04 (0.92–1.18) |
| 3 | 19 | 32 | 1.20 (1.04–1.38) | 21 | 0.97 (0.87–1.08) | 1.01 (0.86–1.18) |
| >3 | 19 | 32 | 1.28 (1.08–1.50) | 19 | 0.88 (0.79–0.98) | 0.94 (0.78–1.14) |
|
| ||||||
| Female | 10 | 28 | 1 | 21 | 1 | 1 |
| Both sexes | 44 | 31 | 0.98 (0.84–1.14) | 21 | 0.96 (0.84–1.09) | 1.05 (0.89–1.23) |
| Male | 46 | 32 | 1.16 (1.02–1.32) | 21 | 0.97 (0.86–1.10) | 0.99 (0.88–1.13) |
|
| ||||||
| 30–45 | 6 | 30 | 1 | 20 | 1 | 1 |
| 46–60 | 81 | 31 | 1.05 (0.91–1.20) | 21 | 1.05 (0.91–1.22) | 1.09 (0.94–1.27) |
| >60 | 13 | 31 | 1.10 (0.93–1.30) | 20 | 0.98 (0.83–1.17) | 0.96 (0.80–1.14) |
|
| ||||||
| >0–1 | 4 | 32 | 1 | 21 | 1 | 1 |
| >1–2 | 38 | 32 | 1.03 (0.85–1.26) | 20 | 0.95 (0.78–1.16) | 1.04 (0.84–1.27) |
| >2–3 | 37 | 31 | 1.03 (0.84–1.27) | 21 | 1.00 (0.82–1.22) | 1.12 (0.90–1.39) |
| >3 | 21 | 30 | 0.97 (0.78–1.22) | 21 | 0.98 (0.80–1.21) | 1.07 (0.85–1.35) |
|
| ||||||
| 0–⅓ | 15 | 31 | 1 | 22 | 1 | 1 |
| >⅓–⅔ | 72 | 31 | 1.04 (0.93–1.15) | 21 | 0.93 (0.84–1.03) | 0.99 (0.89–1.09) |
| >⅔–1 | 13 | 30 | 1.06 (0.92–1.21) | 21 | 0.96 (0.84–1.10) | 1.02 (0.89–1.17) |
|
| ||||||
| 45–70 | 23 | 30 | 1 | 20 | 1 | 1 |
| >70–75 | 55 | 32 | 0.90 (0.82–0.98) | 21 | 0.99 (0.90–1.10) | 1.03 (0.94–1.13) |
| >75 | 22 | 32 | 0.82 (0.73–0.91) | 21 | 1.04 (0.93–1.16) | 1.02 (0.92–1.14) |
|
| ||||||
| 0–0.5 | 6 | 32 | 1 | 22 | 1 | 1 |
| >0.5–1 | 30 | 32 | 0.89 (0.76–1.04) | 21 | 0.92 (0.79–1.08) | 0.91 (0.78–1.06) |
| >1–1.5 | 39 | 30 | 0.82 (0.71–0.96) | 20 | 0.87 (0.75–1.01) | 0.87 (0.75–1.02) |
| >1.5–2 | 18 | 32 | 0.84 (0.71–0.98) | 21 | 0.91 (0.78–1.07) | 0.89 (0.75–1.05) |
| >2 | 7 | 31 | 0.80 (0.67–0.96) | 24 | 1.11 (0.91–1.36) | 1.02 (0.84–1.24) |
|
| ||||||
| 0–2 | 3 | 29 | 1 | 20 | 1 | 1 |
| >2–5 | 19 | 31 | 1.10 (0.90–1.34) | 22 | 1.10 (0.87–1.37) | 1.15 (0.93–1.42) |
| >5–10 | 17 | 30 | 1.14 (0.92–1.40) | 20 | 0.98 (0.78–1.23) | 1.08 (0.86–1.36) |
| >10–20 | 29 | 30 | 1.14 (0.92–1.41) | 20 | 0.94 (0.76–1.17) | 1.08 (0.85–1.36) |
| >20–30 | 20 | 32 | 1.30 (1.04–1.63) | 21 | 0.99 (0.80–1.24) | 1.19 (0.93–1.52) |
| >30 | 12 | 34 | 1.36 (1.07–1.74) | 22 | 1.07 (0.85–1.33) | 1.23 (0.95–1.59) |
|
| ||||||
| 0 | 41 | 31 | 1 | 21 | 1 | 1 |
| >0–5 | 6 | 28 | 0.81 (0.68–0.96) | 19 | 0.84 (0.72–0.99) | 0.96 (0.81–1.15) |
| >5–10 | 21 | 31 | 0.94 (0.84–1.04) | 20 | 0.95 (0.86–1.05) | 1.01 (0.90–1.13) |
| >10–15 | 16 | 32 | 0.98 (0.88–1.09) | 21 | 0.95 (0.85–1.06) | 0.97 (0.87–1.09) |
| >15–20 | 6 | 33 | 1.05 (0.92–1.18) | 22 | 0.99 (0.84–1.16) | 1.03 (0.89–1.20) |
| >20 | 10 | 31 | 0.94 (0.83–1.06) | 20 | 0.95 (0.83–1.09) | 0.91 (0.80–1.04) |
|
| ||||||
| 0–10 | 10 | 33 | 1 | 19 | 1 | 1 |
| >10–25 | 14 | 30 | 0.87 (0.76–0.99) | 22 | 1.16 (0.99–1.35) | 1.19 (1.02–1.38) |
| >25–50 | 28 | 31 | 0.95 (0.84–1.08) | 21 | 1.09 (0.94–1.25) | 1.12 (0.97–1.30) |
| >50–75 | 27 | 31 | 0.98 (0.86–1.12) | 21 | 1.11 (0.96–1.28) | 1.16 (1.00–1.35) |
| >75–90 | 14 | 33 | 1.00 (0.87–1.15) | 21 | 1.07 (0.91–1.25) | 1.16 (0.99–1.36) |
| >90–100 | 7 | 29 | 0.90 (0.77–1.06) | 20 | 1.06 (0.87–1.29) | 1.09 (0.90–1.33) |
|
| ||||||
| 0–65 | 5 | 32 | 1 | 22 | 1 | 1 |
| >65–75 | 18 | 31 | 0.97 (0.83–1.14) | 20 | 0.90 (0.77–1.06) | 0.95 (0.82–1.11) |
| >75–85 | 20 | 31 | 0.99 (0.84–1.16) | 19 | 0.83 (0.72–0.96) | 0.91 (0.79–1.06) |
| >85–95 | 21 | 33 | 1.10 (0.92–1.30) | 21 | 0.92 (0.80–1.07) | 1.00 (0.85–1.18) |
| >95–99 | 17 | 32 | 0.98 (0.81–1.18) | 21 | 0.94 (0.81–1.10) | 1.05 (0.87–1.26) |
| >99 | 19 | 28 | 0.86 (0.71–1.05) | 22 | 1.03 (0.88–1.19) | 1.14 (0.95–1.38) |
Abbreviations: adjusted, adjusted for calendar year and all variables listed in the table; CI, confidence interval; COPD, chronic obstructive pulmonary disease; GP, general practitioner; HR, hazard rate ratio; OR, odds ratio; Total, all 15,525 first-time COPD-hospitalised patients.
[Squared brackets] denote means. Patients referred to in the squared brackets are the other first-time COPD-hospitalised patients listed with the same general practice as the patient in question.
Figure 2The x axis shows the general practice home visit tendency, that is, the proportion of other first-time COPD-hospitalised patients listed with the patient’s practice who had a home visit in the year before hospitalisation. The bars show the distribution of all first-time COPD-hospitalised patients according to their practice’s home visit tendency. The dots show adjusted hazard rate ratios (HRs) compared with the reference group of patients whose practice had a home visit tendency of >20–30%. Vertical lines show 95% confidence intervals for the HRs.
Figure 3Kaplan–Meier curves of first-time COPD-hospitalised patients’ readmission-free survival according to the practice’s home visit tendency. Readmission-free survival is poorer, the more general practitioner home visit tendency (GPHVT) is either lower (left) or higher (right) compared with >20–30% of patients receiving a home visit.